Combination of static magnetic field and cisplatin in order to reduce drug resistance in cancer cell lines

Abstract

Purpose: In this study, the effects of different intensities of Static Magnetic Fields (SMFs) (10, 15 and 25 mT) and different concentrations of cisplatin drug were investigated on the viability percent and IC₅₀ of the A2780 and A2780-CP cell lines at 24, 48 and 96 h to show useful potential of SMF as a physical agent to enhance the effectiveness of common therapeutic approaches and decrease of drug resistance to cisplatin anticancer drug.

Materials and methods: Magnetic field exposure was performed using a locally designed generator. The cell viability percent, IC₅₀ and cisplatin uptake in treated cells were evaluated by MTT assay and inductively coupled plasma (ICP), respectively.

Results: Increasing of concentration and time of cisplatin drug showed a noticeable decrease in viability percent in sensitive and resistant cell lines compared with control group. These decreases were more significant in resistant cells compared with sensitive cells. The obtained IC₅₀ values for resistant were greater than the values obtained for A2780 cells. ICP analysis demonstrated an increased uptake of cisplatin after treatment for 48 and 96 h relative to untreated groups in both resistant and sensitive cells.

Conclusion: Results showed that A2780 cells were more sensitive to cisplatin than A2780-CP. Studies have shown that SMF can increase the effect of cisplatin on cell viability percent and decrease the resistance of A2780-CP cells by producing large, verruca shaped structures at the surface of the cell membrane.

Keywords:

• Cisplatin
• static magnetic field
• A2780-CP cells
• sensitive cells

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Notes on contributors

Amir Jalali

Amir Jalali received his PhD degree in Toxicology from Toxicology department, Shaheed Beheshti University in 2005. He worked in Toxicology department, Leuven University, Belgium in order to complete educational courses in PhD within 6 months. He has joined the school of Pharmacy at Jundishapur University of Medical Sciences since 2006.

Jaber Zafari

Jaber Zafari is PhD of Toxicology from Jundishapur University of Medical Sciences in 2017. He has joined the Azad University scince 2018 and Managing Director of Zistpajooh Afra Co.

Fatemeh Javani Jouni

Fatemeh Javani Jouni received her PhD degree in Biophysics from biological sciences department, Tarbiat Modares University in 2013. She has joined the Azad University scince 2014.

Parviz Abdolmaleki

Parviz Abdolmaleki is professor of Biophysics in Tarbiat Modares University. Ph.D in Medical Physics, Kyushu University, Fukouka, Japan. Title of Ph.D. thesis: Computational evaluation of clinical data using artificial neural networks.

Farshad H. Shirazi

Farshad H. Shirazi is professor of Toxicology in Shahid Beheshti University of Medical Sciences.He published more than 90 scientific publications and 5 chaptersand has supervised about 50 students. He is a member of the working group of Ethics and Autonomy in FIP, and a member of the editorial board on WHO World Pharmacopeia.

Mohammad Javad Khodayar

Mohammad Javad Khodayar is Assistant Professor of Toxicology. He currently works at the Toxicology Department, Ahvaz Jundishapur University of Medical Sciences. Their current project is 'Removal of Ametryn From Aqueous Solutions With Zeolite Nanoparticles Optimized Using the Box-Behnken Design'.